Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Histamine-release Inhibitor
Panaxydiol is a histamine-release inhibitor that effectively suppresses histamine secretion in biological systems. This compound features an alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), facilitating the formation of diverse chemical linkages. Its unique properties make Panaxydiol a valuable reagent for researchers involved in chemical biology, drug discovery, and the development of innovative therapeutic strategies. -
Histamine Receptor Inhibitor
AM-0466 is a selective histamine receptor inhibitor primarily targeting voltage-gated sodium channel NaV1.7. This compound demonstrates potent anti-pruritic activity in histamine-induced itch models and exerts significant analgesic effects in capsaicin-induced pain assays. Its optimized pharmacokinetic profile supports its use in advanced in vivo research for evaluating efficacy in pain modulation and itch relief. -
Histamine Receptor Inhibitor
Fenethazine is a histamine receptor inhibitor known for its antihistamine activity. It effectively alleviates allergic reactions and related symptoms. Additionally, its structural congeners exhibit anticholinergic effects, making fenethazine a candidate for research into therapeutic interventions for Parkinson's disease. This compound is valuable for studies focused on histaminergic pathways and associated disorders. -
Histamine H3 Receptor Antagonist/Serotonin Transporter Inhibitor
JNJ-28583867 is a selective histamine H3 receptor antagonist with a Ki of 10.6 nM and an inhibitor of the serotonin transporter (SERT) with a Ki of 3.7 nM. This compound shows promise in modulating neurotransmitter systems and can be utilized in research focusing on depression and related neuropsychiatric disorders. Its unique mechanism makes it a valuable tool for studying the interplay between histaminergic and serotonergic pathways. -
Histamine Receptor Inhibitor
(R)-Azelastine hydrochloride is a histamine receptor inhibitor that effectively down-regulates the expression of H1, M1, and M3 receptors. This compound exhibits notable biological activity by inhibiting the proliferation of human nasal epithelial cells (HNEpC). Its applications in research include studying allergic reactions and evaluating the roles of histamine receptors in various cellular processes. -
Histamine Receptor Inhibitor
Linadryl is a histamine receptor inhibitor that exhibits antihistaminic properties. It demonstrates a moderate impact on gastric acid secretion following oral administration, approximately half that of Diphenhydramine. Linadryl is primarily utilized in research focusing on allergic responses, gastrointestinal function, and exploring the broader effects of histamine modulation in various biological systems. -
Histamine H1 Receptor Inhibitor
SUN-1334H free base is a potent orally active inhibitor of the histamine H1 receptor, demonstrating an IC50 of 20.3 nM and a Ki value of 9.7 nM. This compound effectively inhibits histamine-induced contractions in isolated guinea-pig ileum with an IC50 of 0.198 μM. SUN-1334H free base has significant applications in research related to bronchoconstriction, allergic responses, and rhinitis, as evident in its ability to mitigate histamine-induced bronchoconstriction in guinea pigs, skin wheals in beagle dogs, and ovalbumin-induced rhinitis in guinea pigs. -
PDE3/PDE4/PDE5/HRH1 Inhibitor
Fenspiride is a potent inhibitor of phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4), and phosphodiesterase 5 (PDE5), with -log IC50 values of 3.44, 4.16, and approximately 3.8, respectively. Additionally, it acts as an antagonist of the H1-histamine receptor, contributing to its anti-inflammatory properties. Fenspiride is primarily utilized in research related to respiratory diseases, offering insights into mechanisms of action and potential therapeutic applications. -
Histamine Receptor Inhibitor
VUF14738 is a bidirectional photoswitch antagonist targeting the histamine H3 receptor. This compound exhibits rapid and reversible photoisomerization, allowing for modulation of binding affinity in response to illumination. Its unique properties make VUF14738 ideal for real-time electrophysiological studies, facilitating research into the dynamic light modulation of receptor activation and the underlying mechanisms of histamine signaling. -
EBOV/MARV Inhibitor
CP19 is a histamine receptor antagonist that functions as an entry inhibitor for both Ebolavirus (EBOV) and Marburgvirus (MARV), demonstrating IC50 values of 3.4 μM and 29.5 μM, respectively. With selectivity index (SI) values of 29.4 for EBOV and 3.4 for MARV, CP19 exhibits notable antiviral activity. This compound is valuable for research into viral entry mechanisms and the development of antiviral strategies targeting EBOV and MARV. -
Histamine Receptor Inhibitor
Mequitamium iodide is a potent histamine receptor inhibitor, demonstrating significant antiallergic and bronchodilatory properties. It effectively antagonizes airway contraction and inflammatory responses triggered by histamine and various antigens, exhibiting nanomolar affinity for H1 and smooth muscle receptors. When delivered via aerosol, Mequitamium iodide markedly reduces histamine- and antigen-induced airway pressure increases in allergic mouse models. Additionally, it decreases eosinophil accumulation in the airways and inhibits platelet aggregation and bronchoconstriction induced by PAF. This compound is valuable for investigating allergic diseases, including rhinitis and asthma. -
Histamine Receptor Inhibitor
Impentamine dihydrobromide is a histamine H3 receptor antagonist known for its potent antihistamine activity. This compound demonstrates selective H3 antagonism, with a pA2 value of 8.4, indicating significant efficacy in guinea pig jejunum studies. Impentamine dihydrobromide binds specifically to the H3 receptor, making it valuable for research in neuropharmacology and related fields investigating histamine's role in neurotransmission and various physiological processes. -
Gastric Secretory Inhibitor
UK-9040 is an orally active inhibitor of gastric secretion that targets histamine receptors. This compound effectively reduces gastric acid, pepsin, and volume output in response to food, insulin, histamine, N-methyl histamine, and pentagastrin. UK-9040 is valuable for research applications focused on gastric physiology and the modulation of acid secretion. -
Histamine Receptor Inhibitor
Hetramine is a histamine receptor inhibitor known for its antihistamine and antiallergic properties. It effectively prevents histamine-induced intestinal contractions and mitigates allergic responses, including anaphylactic shock, in animal models such as guinea pigs. This compound is useful in research related to allergy mechanisms and gastrointestinal function. -
Histamine H3 Antagonist/Serotonin Reuptake Inhibitor
Histamine H3 antagonist-1 is a potent histamine H3 receptor antagonist and serotonin reuptake inhibitor, playing a critical role in neuromodulation. Its primary biological activity makes it valuable for research in the field of depression and related neuropsychiatric disorders. This compound offers insights into the interactions between histamine and serotonin signaling pathways, facilitating the development of novel therapeutic strategies. -
Histamine Receptor Inhibitor
Perphenazine-d8 dihydrochloride is a deuterium-labeled derivative of Perphenazine, primarily functioning as a histamine receptor inhibitor. This compound exhibits potent antipsychotic properties by interacting with serotonin and dopamine receptors. It is valuable for research focused on neuropharmacology, chemical biology, and the study of receptor-ligand interactions in psychiatric disorders. -
Histamine Receptor Inhibitor
(R)-Azelastine is a histamine receptor inhibitor with notable antiallergic properties. This compound effectively downregulates the levels of H1R, M1R, and M3R, making it significant for research related to allergy and inflammation. Additionally, (R)-Azelastine has been demonstrated to inhibit the proliferation of human nasal epithelial cells (HNEpC), indicating its potential applications in studies of respiratory conditions and allergic responses. -
Histamine Release Inhibitor
Acreozast (TYB-2285) is a potent histamine release inhibitor that acts by blocking the release of histamine primed with interleukin-3 (IL-3). This compound has demonstrated the potential to modulate allergic inflammation in vivo through the suppression of inflammatory mediators. Acreozast is of particular interest for research applications involving allergy and immune response studies. -
Histamine Receptor Inhibitor
Azatadine is a histamine receptor inhibitor that functions by antagonizing H1 and H2 subtypes. This compound exhibits significant biological activity in blocking histamine-mediated processes, making it valuable in research related to allergic responses and motion sickness. Azatadine's mechanism of action also extends to cholinergic pathways, providing further insights into neuropharmacological studies. -
5-HT Receptor Inhibitor
Proxibarbal is a barbiturate derivative that acts as a selective inhibitor of the 5-HT receptor. It demonstrates notable anti-anxiety properties and is utilized in research focused on migraine headache mechanisms. This compound serves as a valuable tool for understanding serotonergic pathways and their implications in anxiety and migraine disorders. -
Histamine Receptor Inhibitor
(S)-Azelastine is a selective antihistamine that primarily targets the histamine H1 receptor. This compound exhibits antiallergic and antiasthmatic properties, demonstrating the ability to downregulate levels of histamine receptors H1R, M1R, and M3R. Additionally, (S)-Azelastine has been found to inhibit the proliferation of human nasal epithelial cells, making it a valuable reagent for research in allergy and asthma mechanisms. -
Histamine Inhibitor
Elbanizine is a potent histamine inhibitor that effectively suppresses histamine and bradykinin release from rat mast cells, demonstrating an IC50 of 0.26 μM. This compound has been shown to inhibit IgE-mediated passive cutaneous anaphylaxis (PCA) reactions. Additionally, Elbanizine exhibits significant antiallergic and antiasthmatic properties in guinea pig models, making it a valuable tool for research in allergy and asthma mechanisms. -
Dopamine Receptor Inhibitor
BL-1020 mesylate is a dopamine receptor inhibitor with high affinity for D2L, D2S, and 5-HT2A receptors, exhibiting Ki values of 0.066, 0.062, and 0.21 nM, respectively. This compound functions as an antipsychotic agent and also acts as an agonist at the GABAA receptor, enhancing GABA release with a Ki of 3.74 μM. Furthermore, BL-1020 mesylate interacts effectively with histamine receptors (Ki of 0.47 nM) and demonstrates the ability to diminish amphetamine-induced hyperactivity while minimizing catalepsy and sedation. It penetrates the blood-brain barrier, making it suitable for neurological research applications. -
Histamine Receptor Inhibitor
D18024 is a potent histamine receptor inhibitor that demonstrates antiallergic and antihistaminic properties. This compound exhibits significant activity in modulating histamine-mediated processes, making it useful for research focused on allergy and inflammation pathways. D18024 can be employed in studies investigating the role of histamine receptors in various biological systems, contributing to the understanding of allergic responses and potential therapeutic interventions. -
Histamine Receptor Inhibitor
CI-949 is a potent histamine receptor inhibitor known for its ability to suppress the release of key allergic mediators. It demonstrates inhibition of histamine, leukotriene C4/D4, and thromboxane B2 with IC50 values of 11.4 μM, 0.5 μM, and 0.1 μM, respectively. This compound is useful for studies focused on allergic reactions and inflammation, providing insights into therapeutic strategies for allergic conditions. -
Histamine Receptor Inhibitor
KP136 is a potent histamine receptor inhibitor that exhibits antiallergic properties. It effectively blocks histamine release with an IC50 of 76.1 μg/mL and degranulation at 63 μg/mL. This compound is valuable for research applications focusing on allergic responses and related inflammation processes. -
DPP4 Inhibitor
Sitagliptin hydrochloride is a selective DPP4 inhibitor, demonstrating an IC50 of 19 nM. By inhibiting DPP4, this compound prevents the breakdown of incretin hormones, such as GLP-1 and GIP, ultimately increasing their active levels. Additionally, sitagliptin can stimulate GLP-1 secretion from intestinal L cells via the cAMP/PKA and ERK1/2 pathways, independent of DPP-4 inhibition. This reagent is applicable in research involving type 1 and type 2 diabetes, and it also exhibits protective effects on pancreatic islet grafts in type 1 diabetes models. -
ICMT Inhibitor
POP-3MB is an inhibitor of Isoprenylcysteine carboxyl methyltransferase (ICMT), with an IC50 value of 2.5 μM. It effectively alters the subcellular localization of K-Ras, leading to inhibition of Ras activation. Additionally, POP-3MB demonstrates the capacity to inhibit Erk phosphorylation, making it a valuable tool for research into Ras signaling pathways and related oncogenic processes. -
S1P2 Receptor Inhibitor
S118 is an orally active inhibitor of the sphingosine-1-phosphate receptor 2 (S1P2 receptor), which blocks the binding of Dpr1, subsequently reducing β-catenin accumulation. This mechanism inhibits nuclear translocation of the S1P2 receptor, contributing to the attenuation of inflammation, fibrosis, and epithelial-mesenchymal transition (EMT). S118 demonstrates potential for use in research related to idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. -
Platelet Aggregation Inhibitor
12(S)-HETrE is a fatty acid metabolite that serves as a potent inhibitor of platelet aggregation. This compound demonstrates significant biological activity in modulating thrombus formation and is valuable in thrombosis-related research applications. Researchers can utilize 12(S)-HETrE to study the molecular mechanisms underlying platelet function and explore potential therapeutic targets in cardiovascular diseases. -
PTP4A3 Inhibitor
JMS-053 is a potent and reversible inhibitor of PTP4A3, with an IC50 value of 18 nM. This compound also exhibits significant inhibitory activity against PTP4A1 and PTP4A2, with IC50s of 50 nM and 53 nM, respectively. Additionally, JMS-053 demonstrates inhibition of CDC25B and DUSP3 with IC50 values of 92.6 nM and 207.6 nM, respectively. Through mechanisms such as interference with RhoA and STAT3/p38 signaling pathways, JMS-053 effectively suppresses tumor cell proliferation and migration, making it a valuable tool for investigating various cancers, including ovarian, breast, and colon cancer. -
CXCR4/STAT3 Inhibitor
Minecoside is a potent inhibitor of the CXCR4 receptor and STAT3 signaling pathway. It demonstrates significant anticancer and anti-inflammatory activities by downregulating CXCR4 expression and suppressing STAT3 activation, which leads to the inhibition of CXCL12-induced cellular invasion. Minecoside has been shown to effectively hinder cancer metastasis and enhance apoptosis, making it a valuable tool for research in cancer biology and therapeutic development. -
S1P Inhibitor
Pro-FTY is a sphingosine-1-phosphate (S1P) inhibitor functioning as an anticancer prodrug derived from FTY720. It selectively disrupts S1P signaling in cancer cells using a drug delivery system that reacts with acrolein, demonstrating significant cytotoxic effects on breast cancer cells, including multidrug-resistant variants. Pro-FTY effectively suppresses tumor growth in xenograft models with 4T1 cells and organoids, while maintaining immune cell integrity by avoiding lymphocytopenia. This reagent is valuable for research in cancer therapy and resistance mechanisms. -
Histamine receptors inhibitor
Histamine Receptors Inhibitor 1 (compound 303) functions as an inhibitor of H1 and H4 histamine receptors. This compound demonstrates key biological activity in modulating inflammatory processes and is particularly relevant for research applications focusing on autoimmune, allergic, and ocular conditions. Its ability to selectively inhibit these receptors makes it a valuable tool for investigating histamine-mediated pathways in various biological contexts. -
PDD4 Inhibitor
Sitagliptin phosphate is a selective DPP4 inhibitor with a powerful mechanism of action, featuring an IC50 value of 19 nM. By inhibiting DPP4, this compound prevents the degradation of incretins such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), resulting in enhanced active incretin levels. Additionally, it can directly stimulate GLP-1 secretion from intestinal L cells via the cAMP/PKA and ERK1/2 pathways, which operates independently of DPP-4. Sitagliptin phosphate is valuable for researching both type 1 and type 2 diabetes and demonstrates protective effects on pancreatic islet grafts in type 1 diabetes models. -
Platelet Aggregation Inhibitor
Notoginsenoside Fc is a protopanaxadiol-type saponin derived from the leaves of Panax notoginseng, functioning primarily as a platelet aggregation inhibitor. This compound effectively mitigates platelet aggregation and has been shown to enhance reendothelialization after vascular injury in diabetic rat models by promoting autophagy. Its biological activity makes Notoginsenoside Fc a valuable reagent for research in cardiovascular health and vascular regeneration. -
CB1 Receptor Inhibitor
Pregnenolone monosulfate sodium (3β-Hydroxy-5-pregnen-20-one monosulfate sodium) is a selective inhibitor of the cannabinoid CB1 receptor. This neurosteroid, a key precursor in steroid hormone synthesis, can mitigate the effects of tetrahydrocannabinol (THC) by blocking its action at CB1 receptors. Additionally, Pregnenolone monosulfate sodium serves as a TRPM3 channel activator and has been shown to weakly activate TRPM1 channels. Its unique properties make it a valuable tool for investigating cannabinoid signaling and neuroprotective strategies against cannabis-related effects. -
CB1 Receptor Inhibitor
Pregnenolone monosulfate (3β-Hydroxy-5-pregnen-20-one monosulfate) is a selective inhibitor of the cannabinoid CB1 receptor. By inhibiting the effects of tetrahydrocannabinol (THC) mediated through the CB1 receptors, it offers potential neuroprotective properties against cannabis intoxication. Additionally, Pregnenolone monosulfate serves as a TRPM3 channel activator and exhibits weak activation of TRPM1 channels, making it valuable for research in neuropharmacology and cannabinoid signaling pathways. -
Icmt Inhibitor
Cysmethynil is an inhibitor of Isoprenylcysteine carboxylmethyltransferase (Icmt) with an IC50 of 2.4 μM. It disrupts RAS membrane binding and interferes with EGF signal transduction, leading to cell cycle arrest in the G1 phase and the induction of autophagy. Cysmethynil effectively inhibits the proliferation of PC3 prostate cancer cells and demonstrates synergistic effects with chemotherapeutic agents such as Paclitaxel and Doxorubicin. This compound is applicable for research into solid tumors, including prostate cancer. -
5-HT Reuptake Inhibitor
Mesembrine, also known as (+)-Mesembrine, is a potent inhibitor of the 5-HT transporter with a Ki value of 1.4 nM. This alkaloid, characterized by its aryloctahydroindole structure, also inhibits phosphodiesterase 4B (PDE4B) with an IC50 of 7.8 μM. Due to its selective targeting of serotonin reuptake, Mesembrine is valuable for studies related to mood regulation and various neuropsychiatric disorders, as well as investigations into PDE4B's role in inflammatory processes. -
β₂-adrenergic receptor Agonist/PDE4 Inhibitor
GS-5759 is a dual-action compound functioning as a β₂-adrenergic receptor agonist and a phosphodiesterase 4 (PDE4) inhibitor. By activating the β₂ receptor, GS-5759 elevates intracellular cAMP levels, resulting in bronchial dilation. Additionally, its inhibition of PDE4 activity decreases cAMP degradation, thereby enhancing anti-inflammatory responses. This compound is relevant for research into respiratory disorders, particularly chronic obstructive pulmonary disease (COPD), demonstrating significant bronchodilatory and anti-inflammatory effects in preclinical models. -
LPA Antagonist/ATX Inhibitor
BrP-LPA is a potent lysophosphatidic acid (LPA) antagonist and autotoxin (ATX) inhibitor. It exhibits broad-spectrum antagonism against LPA receptors LPA1-4, resulting in decreased blood vessel density and reduced anxiety-like behaviors. Additionally, BrP-LPA demonstrates significant anticancer activity, effectively inhibiting cell proliferation in breast, colon, and lung cancer models. This compound is valuable for research focused on cancer biology and vasculature modulation. -
hA2A AR/hCA XII Inhibitor
hA2A/hCA XII modulator 1 is a potent inhibitor of the human A2A adenosine receptor (hA2AAR) and human carbonic anhydrase XII (hCA XII). It demonstrates high affinity with IC50 values of 6.4 nM for hA2AAR and 6.2 nM for hCA XII, while exhibiting selectivity against other adenosine receptor subtypes and carbonic anhydrases. This compound is valuable for cancer research, particularly in studies related to tumor microenvironment modulation and metabolic pathways involving adenosine signaling and carbonic anhydrase activity. -
DPP-IV Inhibitor
AGFAGDDAPR is a competitive and orally active inhibitor of dipeptidyl peptidase-IV (DPP-IV). By inhibiting DPP-IV, AGFAGDDAPR increases levels of glucagon-like peptide-1 (GLP-1), which stimulates insulin secretion, enhances β-cell function, and suppresses excessive α-cell proliferation, resulting in beneficial anti-diabetic effects. This peptide is suitable for investigating mechanisms and therapeutic approaches related to type 2 diabetes. -
DPPIV Inhibitor
K579 is a potent dipeptidyl peptidase IV (DPPIV) inhibitor that exhibits oral bioactivity. This compound effectively mitigates blood glucose elevation by increasing plasma insulin levels and enhancing the active forms of glucagon-like peptide-1 (GLP-1). K579 is suitable for research applications focused on diabetes and glucose metabolism regulation. -
DPP-4 Inhibitor
(2S,4R)-Teneligliptin is a selective inhibitor of dipeptidyl peptidase IV (DPP-4). By enhancing the plasma concentration of active glucagon-like peptide-1 (GLP-1), it promotes insulin secretion in response to elevated blood glucose levels, demonstrating significant hypoglycemic activity. This compound holds promise for research applications focused on type 2 diabetes management and related metabolic disorders. -
Dipeptidyl Peptidase Inhibitor
Retagliptin hydrochloride is an effective inhibitor of dipeptidyl peptidase-4 (DPP-4), a key enzyme in glucose metabolism. This compound enhances glycemic control in type 2 diabetes by prolonging the action of incretin hormones, including glucagon-like peptide-1 (GLP-1). It is utilized in research applications focused on metabolic disorders and the regulation of insulin secretion. -
DPP4 Inhibitor
Cetagliptin is an orally active dipeptidyl peptidase 4 (DPP-4) inhibitor that also engages CYP2D6 with an IC50 value of 6 µM. By inhibiting DPP-4, cetagliptin effectively reduces the degradation of glucagon-like peptide-1 (GLP-1), contributing to the regulation of postprandial blood glucose levels. This compound is primarily utilized in type 2 diabetes mellitus research, making it a valuable tool for studying glucose homeostasis and metabolic responses. -
DPP-4 Inhibitor
DPP-4-IN-18 is a potent and selective Dipeptidyl Peptidase-4 (DPP-4) inhibitor with an IC50 of 27 nM. By inhibiting DPP-4, this compound prevents the degradation of glucagon-like peptide 1 (GLP-1), leading to increased levels of active GLP-1. DPP-4-IN-18 is primarily utilized in research focused on type 2 diabetes and related metabolic disorders. -
DPP-IV Inhibitor
Gosogliptin hydrochloride is a selective, competitive inhibitor of DPP-IV, an enzyme crucial for the degradation of incretin peptides such as GLP-1 and glucose-dependent insulinotropic polypeptide. This compound exhibits rapid and reversible inhibition of plasma DPP-4 activity, leading to enhanced insulin secretion and improved glucose tolerance. Gosogliptin hydrochloride is primarily utilized in research focused on diabetes and metabolic disorders, providing valuable insights into glucose regulation and insulin dynamics.
